FLGT - Buy One Fulgent Get COVID-19 Testing Business Free

• Fulgent has a successful genetic testing business growing at 50% that should benefit from the reduced cost of sequencing.
• However, more recently, Fulgent's COVID-19 business has seen greater success and is expected to quadruple total revenue this year.
• Comparing Fulgent with comparable companies show that the market is attributing little to no value to this very valuable COVID-19 business.
• Our estimates show that based on multiples of other COVID-19 testing pure-play businesses like CODX, Fulgent could be undervalued substantially.

For further details see: